A major hurdle in the development of effective treatments for amyotrophic lateral sclerosis
(ALS) has been the lack of robust biomarkers for use as clinical trial endpoints …

The main objective of this study was to utilize high field (7T) in vivo proton magnetic
resonance imaging to increase the ability to detect metabolite changes in people with ALS …

Introduction Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative
disorder primarily affecting upper and lower motor neurons. Due to relative fast progression …

In vivo proton magnetic resonance spectroscopy (MRS) may be used to quantify brainstem
neuronal degeneration in ALS because of the neuronal localization of N-acetylaspartate and …

Proton magnetic resonance spectroscopy (1H-MRS) and proton magnetic resonance
spectroscopic imaging (1H-MRSI) have been used to identify neuronal dysfunction and/or …

Background Clinical assessment is insensitive to the degree of cerebral involvement in
amyotrophic lateral sclerosis (ALS). Regional brain concentrationsN …

BACKGROUND AND PURPOSE: Frontotemporal lobar degeneration is responsible for the
cognitive abnormalities seen in patients with ALS. We sought to evaluate the in vivo …

Biomarkers beyond clinical assessment are needed in patients who suffer from amyotrophic
lateral sclerosis (ALS). Here, single-voxel proton magnetic resonance spectroscopy (1 H …

Proton magnetic resonance spectroscopy (MRS) provides a means of measuring cerebral
metabolites relevant to neurodegeneration in vivo. In amyotrophic lateral sclerosis (ALS) …

We aimed to increase confidence in the combined use of MRI and proton MR spectroscopy
(1 H-MRS) in diagnosis of amyotrophic lateral sclerosis (ALS). We investigated 12 patients …